Skip to main content

Home›Research›Compare›CJC-1295 DAC vs MK-677

Peptide Comparison

CJC-1295 DAC vs MK-677

Both are GH / IGF Axis peptides.

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

15 providers listed

Full CJC-1295 DAC profile →
vs

MK-677

Ibutamoren

PerformanceUnder clinical reviewResearch Only

Half-life: 24 hours

64 providers listed

Full MK-677 profile →
Bottom line

CJC-1295 DAC has a longer half-life than MK-677, so it generally needs less frequent dosing.

Quick Verdict

CJC-1295 DAC

Half-life

6–8 days

MK-677

Half-life

24 hours

Which One Should You Choose?
Your goalBetter option
Stronger clinical evidenceMK-677
Less frequent dosing (longer half-life)CJC-1295 DAC
Oral administration optionMK-677
More provider options (15 vs 64)MK-677

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison
CJC-1295 DAC
MK-677
Mechanism Family
GH / IGF Axis
GH / IGF Axis
Half-life
6–8 days
24 hours
FDA Status
not evaluated
Under clinical review
Admin Routes
subcutaneous
oral
Availability
Research Only
Research Only
Providers
15 listed
64 listed
FDA Update
—
Under clinical review
Avail. Notes
Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.
Non-peptide ghrelin mimetic. Active IND; Phase 2/3 trials by Merck/Helsinn. Never FDA-approved. FDA enforcement actions against MK-677 supplements as unapproved new drug. Investigational only.
Research Evidence

CJC-1295 DAC

RCT · 1 key study · dated evidence base — most recent 2006

MK-677

RCT · 2 key studies · most recent 2018
Research Citations

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas
GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

About MK-677

MK-677 mimics the action of ghrelin by binding to and activating the GHSR-1a receptor in the pituitary gland, stimulating pulsatile GH release. Its oral bioavailability distinguishes it from peptide-based GH secretagogues and its prolonged half-life results in sustained IGF-1 elevation. Research protocols have explored its effects on lean body mass, bone mineral density, and sleep architecture.

Research Areas
oral GH and IGF-1 stimulation without injectionfat-free mass increase documented in RCTsappetite stimulation via ghrelin receptor agonismsustained IGF-1 elevation — long-duration monitoring relevant
Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 DAC

Warnings & Cautions
Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring
IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

MK-677

Warnings & Cautions
Active malignancy — caution (raises GH/IGF-1)Pregnancy — cautionUncontrolled diabetes / insulin resistance (can raise fasting glucose)Known hypersensitivity

Class-based (investigational)

Price (per mg)

CJC-1295 DAC

$11.94/mg

$8.85 – $17.19 range

25 vendors

MK-677

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated October 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 DAC vs MK-677 — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/cjc-1295-dac/mk-677

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.